A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects with Normal Tension Glaucoma (NTG)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QLS 111 (Primary)
Indications Low tension glaucoma
Focus Adverse reactions
Acronyms Nightingale
Sponsors Qlaris Bio

Most Recent Events

14 Mar 2025 Planned number of patients changed from 60 to 36.
14 Mar 2025 Planned End Date changed from 15 Oct 2025 to 22 Oct 2025.
14 Mar 2025 Planned primary completion date changed from 1 Oct 2025 to 15 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight